Armata Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Armata Pharmaceuticals's estimated annual revenue is currently $13.8M per year.
- Armata Pharmaceuticals's estimated revenue per employee is $205,896
- Armata Pharmaceuticals's total funding is $196M.
Employee Data
- Armata Pharmaceuticals has 67 Employees.
- Armata Pharmaceuticals grew their employee count by -6% last year.
Armata Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Corporate Controller | Reveal Email/Phone |
3 | VP, Business and Corporate Development | Reveal Email/Phone |
4 | VP, Program Management and Operations | Reveal Email/Phone |
5 | SVP Finance | Reveal Email/Phone |
6 | SVP Finance and Principal Financial Officer | Reveal Email/Phone |
7 | Scientific Director | Reveal Email/Phone |
8 | Associate Director | Reveal Email/Phone |
9 | Sr. Director Quality Control | Reveal Email/Phone |
10 | Director Manufacturing | Reveal Email/Phone |
Armata Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Armata Pharmaceuticals?
Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing. More information is available at www.armatapharma.com
keywords:N/A
$196M
Total Funding
67
Number of Employees
$13.8M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Armata Pharmaceuticals News
Armata Pharmaceuticals had leased the entire property starting in 2021. CBRE representatives Mike Longo,Todd Tydlaska, Sean Sullivan,...
Stream Realty Partners represented Armata Pharmaceuticals in the lease. Tim Dwight, from Stream Realty, said, "This new facility will allow them...
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of...
MARINA DEL REY, Calif., Aug. 12, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today anno ...
MARINA DEL REY, Calif., Aug. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infection ...
Other Companies in Marina del Rey
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.9M | 68 | 33% | N/A |
#2 | $15.5M | 71 | 29% | N/A |
#3 | $9.8M | 76 | 25% | N/A |
#4 | $12.7M | 77 | 1% | $67M |
#5 | $16.3M | 81 | N/A | N/A |